| Abbas, Ahmed | Using Machine Learning to Predict RNA Pol II Interactions of Metastatic Prostate Cancer |
| Au, CheukMan Cherie | First-in Class AR V7/AR-fl Small Molecule Degrader for Prostate Cancer Therapeutics |
| Bevan, Charlotte | Detection of clinically informative circulating mRNA biomarkers for Prostate Cancer Prognosis Using an ISFET Lab-On-Chip Platform |
| Bhatia, Vipul | Engineering Next-Generation STEAP1 CAR T Cells: Development and Optimization for Enhanced Anti-Tumor Efficacy in Prostate Cancer |
| Brisbane, Wayne | Combining Prostate MRI and Micro-ultrasound to Omit Systematic Biopsy |
| Burnham, Leanne | Community-Based Prostate Screening for Black Men: Changing the Equity Landscape in Metropolitan Atlanta and Rural Georgia |
| Buteau, James | Radiation absorbed dose in patients with metastatic castration-resistance prostate cancer treated with [161Tb]Tb-PSMA-I&T |
| Cesano, Alessandra | Phase 1/2 Trial of Oral Masofaniten (EPI-7386) in Combination with Enzalutamide (Enz) Compared to Enz Alone in Metastatic Castration-Resistance Prostate Cancer (mCRPC) Subjects |
| Chakraborty, Goutam | Chromosome 13q deletion and lethal prostate cancer: Biomarker to cancer therapeutics |
| Cheng, Heather | Prostate screening for people with inherited risk of developing aggressive prostate cancer: The PATROL study |
| Chen, William | Investigating the Biological Basis of Multimodal AI Predictions in Prostate Cancer Using Spatial Single-cell Proteomics |
| Chen, William | Association between radiomic features and outcomes after metastasis-directed radiotherapy |
| Chesner, Lisa | Androgen receptor inhibition increases MHC Class I expression and improves immune response in prostate cancer |
| Cole, Alexander | Use of Advanced Imaging Among United States Medicare Beneficiaries with Prostate Cancer |
| Cook, Leah | Characterization of patient (polymorphonuclear neutrophils) PMNs reveals a novel role for androgen receptor regulation of neutrophil immune response |
| Crawford, Taylor | Association of HOXB13 p.G84E with prostate cancer among 592,158 men |
| Daemen, Anneleen | ORIC-944, a potent and selective allosteric PRC2 inhibitor with best in-class properties demonstrates combination synergy with AR pathway inhibitors in prostate cancer models |
| De Sarkar, Navonil | Truncal Drivers as Key Determinant of Treatment Outcomes in Concurrent High TMB and HRD Metastatic Prostate Cancers |
| Ding, Chien-Kuang Cornelia | Application of Canary Histology Classifier in Prostate Biopsies for Risk Stratification |
| Ding, Chien-Kuang Cornelia | Artificial Intelligence-based Detection of Primary Small Cell Carcinoma of Prostate |
| Dornisch, Anna | Prostate CAncer integrated Risk Evaluation (P-CARE): a model to stratify risk of any, metastatic, and fatal prostate cancer |
| Doultsinos, Dimitrios | The activity of the Unfolded Protein Response Transducer IRE1 is a predictor of treatment resistant disease and a proxy of NEPC and RB1-loss like phenotypes |
| Edwards, Claire | Single-Cell Functional Biology in the Tumor-Bone Microenvironment: Identification of Individual Prostate Cancer Cells with High Metastatic Potential |
| El-Kenawi, Asmaa | ANPEP regulates one-carbon metabolism in prostate cancer |
| Eltit Guersetti, Felipe | Prostate Cancer Metastasis Disrupts Lacuna-Canalicular Network in Trabecular Bone |
| Feng, Weiran | Cell context dependency and vulnerabilities of ERG-driven prostate cancer |
| Flavell, Robert | CD46 targeted theranostics for imaging and treatment of prostate cancer |
| Fletcher, Claire | A Novel MicroRNA-Based Mechanism of DNA Damage in Prostate Cancer Requires Interaction with Topoisomerases and Basal Transcription Machinery |
| Fojo, Antonio | Comparable efficacy of abiraterone and enzalutamide in United States Veterans with metastatic castration-sensitive prostate cancer (mCSPC). An updated analysis. |
| Fonesca, Nicolette | Prediction of ctDNA fraction for genomic biomarker testing and implementation of ctDNA based prognostication in advanced prostate cancer |
| Garzotto, Mark | Phase II study of pembrolizumab plus androgen deprivation therapy in combination with radiotherapy for high-risk localized prostate cancer |
| Godolphin, Peter | Maximising patient benefit through enhanced evaluation of therapies and better characterisation of metastatic hormone-sensitive prostate cancer (mHSPC): STOPCAP M1 – past, present and future |
| Godolphin, Peter | Evaluating the evidence behind treatment recommendations in clinical guidelines for metastatic hormone-sensitive prostate cancer: A systematic review |
| Gong, Jun | A nationwide VA study on systemic treatment patterns in Black men with metastatic castration-resistant prostate cancer: Study update |
| Graff, Rebecca | Sociodemographics in relation to Satisfaction With Cancer Care, Social Support, Self-Efficacy, Barriers, and Change Strategies Among Individuals With Prostate Cancer |
| Grist, Emily | Decipher mRNA score for prediction of survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for advanced prostate cancer (PC): an ancillary study of the STAMPEDE docetaxel trials |
| Grunberg, Nil | Bi-Directional Extracellular Vesicle-Mediated Communication Between Peri-Prostatic Adipose Tissue and Tumour Cells Drives Prostate Cancer Agressivity |
| Gueron, Geraldine | PKA signaling pathway as a key driver of SPP1/OPN expression in prostate cancer bone metastasis |
| Gurel, Bora | Integrative analyses of patterns of CD3 T-cell distribution in metastatic hormone-sensitive castration-resistance prostate cancer |
| Haas, Roni | Divergent Evolution in Bilateral Prostate Cancer: a Case Study |
| Hahn, Andrew | Body composition and the efficacy of pre-operative hormone therapy (HT) for men with localized and/or locally advanced prostate cancer |
| Halabi, Susan | A New Prognostic Model of Overall Survival (OS) in patients (pts) with Metastatic Hormone Sensitive Prostate cancer (mHSPC) |
| He, Househeng Hansen | Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation |
| Hong, Julian | Development of a machine learning model to predict overall survival results from randomized clinical trials of patients with metastatic prostate cancer |
| Hossain, Md Niamat | The αVβ3 integrin/NgR2 complex is upregulated in NEPrCa and is a novel therapeutic target |
| Hsiung, Chris | Engineered CRISPR-Cas12a for higher-order combinatorial chromatin perturbations |
| Hsu, Sarah | Identification of Asporin as a HER3 ligand exposes a therapeutic vulnerability in metastatic prostate cancer |
| Hurley, Paula | Automated AI Tumor Burden Analysis in PSMA & FDG PET and Lu-177 PSMA Quantitative SPECT with Global Threshold Regional Consensus Network (GTRC-Net) |
| Jackson, Price | Automated AI Tumor Burden Analysis in PSMA & FDG PET and Lu-177 PSMA Quantitative SPECT with Global Threshold Regional Consensus Network (GTRC-Net) |
| Jaiswal, Praveen | Digital spatial profiling of ore-and post-treatment GR+ metastatic CRPC from a phase I trial of enzalutamide and a GR antagonist reveals cAMP and MAPK gene expression pathway suppression after treatment |
| Jamaspishvili, Tamara | A Single-center Retrospective Observational Study of Current Management Practices of Localized High/Very-High-Risk and Advanced Hormone Sensitive Prostate Cancer Patients |
| James, Nicholas | The Man Van – Using Mobile Targeted Case-Finding to Address Health Inequalities in Prostate Cancer |
| Jamieson, Christina | Analysis of Wnt5A/ROR1 Signaling Inhibition as Cancer Stem Sell Targeting Therapy for Metastatic Prostate Cancer Using Live Organoid Time Lapse Microscope Imaging |
| Jatwani, Karan | Risk Assessment of Myelosuppression with PARP Inhibitors in Prostate Cancer: Insights from FAERS |
| Jeyapalan, Jennie | Genomic determinants of prostate cancer in Zambian patients |
| Jeyapalan, Jennie | ASH1L methyltransferase: a therapeutic target in prostate cancer? |
| Jeyapalan, Jennie | Epitranscriptomic determinants of enzalutamide resistance |
| Kamran, Sophia | Integrative Profiling of Tumor-Immune Dynamics and Evolution in Response to Radiotherapy for Oligometastatic Prostate Cancer |
| Kanadia, Rahul | Leveraging minor intron classification to target their splicing to treat prostate cancer |
| Kanayama, Mayuko | Clinical and functional characterization of the HOXB13 X285K germline mutation specific to men of African-ancestry |
| Kenfield, Stacey | Self-Efficacy is Associated with Higher Diet Quality Among Men With Prostate Cancer |
| Ketola, Kirsi | Secreted factors from M1 macrophages drive prostate cancer stem cells plasticity by upregulating NANOG SOX2, and CD44 through NFxB- signaling |
| Knudsen, Beatrice | Predicting Metastatic Risk at Diagnosis from Digital Pathology Slides in the VA Health Care System |
| Kotula, Leszek | Defining ABI1-driven mechanism of ezalutamide resistance. |
| Kregel, Steven | Clinically relevant humanized mouse models of metastatic prostate cancer facilitate therapeutic evaluation |
| Ku, Anson | Club-like cells and PIGR expression are associated with inflammatory high-risk, localized prostate cancer |
| Kumar, Rajendra | CRM1 regulates androgen receptor stability and impacts DNA repair pathways in prostate cancer, independent of the androgen receptor |
| Kwan, Edmond | Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of 177Lu-PSMA-617 (LuPSMA) versus cabaitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603) |
| Labanca, Estefania | From Tumor Suppression to Bone Remodeling: The Dual Role of Ra-233 in Advanced Prostate Cancer |
| Labbé, David | FOXA1 control of MYC-driven metabolic adaptation in aggressive prostate cancer |
| Lallous, Nada | Investigating the distinct phase separation properties of androgen receptor isoforms in prostate cancer |
| Leiter, Amanda | Impact of diabetes on cardiovascular outcomes in prostate cancer survivors receiving androgen deprivation therapy |
| Li, Chennan | Harnessing the ower of liquid biopsy for understanding mechanisms of PD-L1/PARP1-targeted therapy resistance in metastatic castration-resistance prostate cancer |
| Li, Haolong | Developing novel PTGES3 inhibitors as next generation agents for mCRPC |
| Li, Yun | Metabolic Modulation of Androgen-Receptor Signaling Inhibitor Mediated Radiosensitization |
| Lorenzin, Francesca | ERG induces persistent inflammatory and senescence-associated responses in prostate cancer |
| Luo, Jie | Oncogenic enhanceosomes are disabled by p300/CBP degradation |
| Lynch, Julie | Incorporating Structured and Unstructured Data Sources to Identify Hereditary Cancer Testing among Veterans with Metastatic Castration-Resistance Prostate Cancer |
| Lyu, Aram | Identification and therapeutic target of myleoid-mediated mechanisms of immunotherapy resistance in prostate cancer |
| Madan, Ravi | A Clinical Trial Combining a Tumor Targeting Immunocytokine (PDS01ADC) and Enzalutamide without Testosterone Lowering Therapy in Biochemically Recurrent Prostate Cancer |
| Mao, Zhiyuan | Tuning TCR Immunotherapy Targeting Prostatic Acid Phosphatase via Catchbond Modifications for Advanced Prostate Cancer |
| Marshall, Catherine | Bipolar androgen therapy (BAT) and dynamics of clonal hematopoiesis |
| Mavingire, Nicole | Investigating the Proteomes and Metabolomes of HER2-positive Prostate Cancer in Response to Trastuzumab Therapy |
| Maynard, Janielle | Androgen Receptor- Mediated Regulation of the Prostate Tumor Microenvironment in Black Men |
| Mei, Shenglin | Single cell and spatial transcriptomics reveal tumor associated macrophages mediate prostate cancer progression and metastasis. |
| Millan, David | AUTX703, a Highly Potent and selective KAT2A and KAT2B Protein Degrader, Induces Cell State Changes and Inhibits Growth in NEPC and SCLC cancers |
| Morel, Katherine | Dimethylaminoparthenolide augments the radiation response in prostate cancer |
| Morris, Michael | Efficacy of [177Lu]Lu-PSMA-617 versus ARPI change in taxane-naive patients with metastatic castration-resistant prostate cancer by pre-randomization ARPI (PSMAfore) |
| Murad, John | Solid tumor CAR T cells engineered with fusion proteins targeting PDL1 for localized IL-12 delivery against prostate cancer |
| Nelson, Colleen | Evexomostat/SDX-7320 demonstrates potent anti-tumor effects across stages of prostate cancer progression, including treatment refractory and neuroendocrine (AAVPC) phenotypes |
| Nickols, Nicholas | Deep learning models built from PSMA PET of the primary tumor can predict synchronous and metachronous prostate cancer metastases |
| Nouruzi, Shaghayegh | ASCL1-Driven Epigenetic and Metabolomics Programs in Neuroendocrine Prostate Cancer |
| Pandey, Apurva | Conditionally activated membrane binding probes for improved targeted radiotherapy in metastatic castration resistant prostate cancer. |
| Papachristodoulou, Alexandros | Aging-associated molecular drivers of mitochondrial dysfunction accelerate prostate carcinogenesis |
| Patel, Krishnan | AIRSTREAM:Artificial Intelligence (AI)-Based Lesion Kinetics Apraisal for the Selection of Therapeutic Targets for Focal Stereotactic Body Radiation Therapy (SBRT) in Patients with Oligoprogessive Metastatic Castration Resistance (mCRPC) |
| Patton, Robert | A deep learning framework for predicting gene expression from cell-free DNA |
| Plymate, Stephen | Increased glycolytic activity in the hypoxic environment is enhanced by P53/RB1 loss |
| Quigley, David | Convergent. evolution of complex structural variants drives therapy resistance in metastatic prostate cancer |
| Rajendran, Rithika | Response of HER2-expressing Prostate Cancer to Trastuzumab Deruxtecan |
| Rajendran, Rithika | The Association and Significance of HER2 and HER3 positivity in Prostate Adenocarcinoma |
| Ravi, Praful | Prognostic impact of residual cancer burden (RCB) on long-term outcomes after neoadjuvant (neo) androgen receptor pathway inhibitor (ARPI) and radical prostatectomy (RP) for high-risk localized prostate cancer (HRLPC): a pooled analysis of phase 2 trials |
| Rhie, Suhn | DNA methylation signatures linked to different grades of prostate tumors from African American and European American patients |
| Rojo, Domingo Mariluz | Restriction Spectrum Imagining as a quantitative biomarker for prostate cancer with reliable positive predictive value |
| Sachdeva, Ashwin | Fracture-related hospitalisations in de novo advanced or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE abiraterone acetate plus prednisone + / – enzalutamide and M1 | RT phase 3 trials using health systems data |
| Sachdeva, Ashwin | Adding metformin to androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC): Overall survival (OS) results from the multi-arm, multi-stage randomised platform trial STAMPEDE |
| Sachdeva, Ashwin | A randomised phase 3 evaluation of transdermal oestradiol (tE2) versus luteinising hormone releasing hormone agonists (LHRHa) for androgen suppression in non-metastatic (0) prostate cancer; efficacy results from the PATCH and STAMPEDE trials. |
| Salari, Keyan | Risk-adapted screening with multiparametric MRI for individuals at high risk of prostate cancer in the PROGRESS study |
| Salji,Mark | Prostate Specific Membrane Antigen (PSMA) related Neuronal Metabolites in Treatment Resistant Prostate Cancer |
| Sanchez, Leslie | Clinical Trials for Prostate Cancer Patients in the VA Medical System |
| Sanin, David | Myleoid Cell Regulation in Patients with Advanced Prostate Cancer treated with Bipolar Androgen Therapy |
| Schafer, Cara | Immune profiling or prostate tumors from a military cohort of African American and Caucasian American patients |
| Schmidt, Daniel | Targeting Pyruvate Kinase to Induce Metabolic Dependencies in Prostate Cancer |
| Shoen, Martin | Comparison of outcomes with docetaxel or ARPI combination therapy for metastatic hormone sensitive prostate cancer (mHSPC) by volume of disease |
| Schweizer, Michael | Phase 1 trial of mevrometostat (PF-06821497), a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in castration-resistant prostate cancer (CRPC) |
| Scurll, Josh | The landscape of genomic alterations and their phenotype association in high-risk localized prostate cancer in the Genomic Umbrella Neoadjuvant Study |
| Semenova, Galina | Targeting Advanced Prostate Cancer with Antibody-Drug Conjugate (ADC) Combinations |
| Sena, Laura | Androgen receptor drives polyamine synthesis creating a vulnerability for prostate cancer |
| Sentana Lledo, Daniel | Genetic Drivers of Quality Of Life in Prostate Cancer – An Evaluation of Genetic Polymorphisms, atient Reported outcomes, and Adverse Events in E3805 CHAARTED trial |
| Shakhnazaryan, Nana | Exploring Social Vulnerability in Prostate Cancer management: Insights from Watchful Waiting and Active Surveillance (1998-2017) |
| Shakhnazaryan, Nonna | Impact of Socioeconomic Status and Community Vulnerability on Treatment Slection and Outcomes in Intermediate and High-Risk Prostate Cancer: A Pathway to Reducing Disparities |
| Sharifi, Marina | High purity CTC RNA sequencing identifies poor prognosis lineage states in castrate resistant prostate cancer |
| Shibata, Maho | Macrophages of multiple hematopoietic origins reside in the developing prostate |
| Shobaki, Nour | Establishing a Preclinical Model to Predict and Mitigate CAR T Cell Toxicity in Prostate Cancer |
| Shrestha, Raunak | An Atlas of Accessible Chromatin in Advanced Prostate Cancer Reveals the Epigenetic Evolution during Tumor Progression |
| Siddiqui, Bilal | A pilot presurgical trial of REGN5678 (Anti-PSMAxCD28) in patients with high-risk, localized prostate cancer followed by radical prostatectomy |
| Sim, Woogwang | PTEN/P53 Altered Prostate Cancer Has Unique Role for Tumor-Associated Macrophage Upon Androgen Signaling Inhibitor Resistance |
| Sjöström, Martin | 5hmC-sequencing of matched cfDNA and tissue from men with mCRPC is concordant and identifies loss of AR signaling in NEPC and DNPC |
| Skog, Johan | Integrative multi-omic analysis of extracellular vesicle transcriptomics profiling combined with cfDNA methylation reveals improved stratification of low-risk and high-risk prostate cancer patients in urine-based liquid biopsy. |
| Soh, Pamela | Role of the Y-chromosome in the ethnic disparities and prostate cancer presentation |
| Sokolova, Alexandra | Concurrent Chemo-Hormonal Therapy of Enzalutamide (ENZ) and Cabazitaxel (CAB) in Patients (Pts) with Metastatic Castration-Resistant Prostate Cancer (mCRPC): Final Analysis of Objective Response Rate (ORR), Radiographic Progression-Free Survival (rPFS), and Overall Survival (OS) |
| Sumiyoshi, Takayuki | Establishment of a novel transcriptome analysis for metastatic castration-sensitive prostate cancer using long-read sequencing technologies |
| Sun, Yue | Nonlinear Microscopy Provides Non-destructive Rapid Pathology Annotations for High-quality Prostatic Tissue Procurement and Translational Research |
| Szempruch, Tony | Discovery of a completely novel class of androgen-competitive AR inhibitors that can combat drug resistance due to AR gene amplification |
| Tabrizian, Nakisa | Receptor Tyrosine Kinase ROR2 as a Candidate for Antibody-Drug Conjugates in Androgen Receptor-Independent Prostate Cancer |
| Takeda, David | Profiling the Prostate Cancer Epigenome Using Circulating Nucleosomes in Plasma |
| Taylor, Amy | Fragmentomics of cell free DNA from targeted panels in genitourinary malignancies |
| Tendler, Salomon | A Theranostic Approach: Therapy of Delta-Like Ligand 3 Expressing Neuroendocrine Prostate Cancer |
| Traphagen, Nicole | Defining the effects of PARP inhibition on androgen receptor function in homologous recombination- proficient prostate cancer |
| Trigos Gomez, Anna | Neuroendocrine, amphicrine and AR + disease across lesions in a single mCRPC patient reveals a link between plasticity and clonal evolution |
| Vazquez, Elba | Unmasking Neuroendocrine Prostate Cancer with a Machine Learning-Driven 7-Gene Stemness Signature that Predicts Progression |
| Venkadakrishnan, Varadha Balaji | EZh2-mediated epigenetic underpinnings in advanced prostate cancer subtypes |
| Wei, Xiao | Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with 177Lu-PSMA-617 versus change of ARPI in PSMAfore |
| Weiner, Adam | Molecular hallmarks of prostate-specific membrane antigen in treatment-naive prostate cancer |
| Wen, Ru | Targeting Siglec-9 immune checkpoint with CD59 as a potential ligand to inhibit prostate cancer progression |
| Wen, Ru | FXYD5 plays diverse roles in immune evasion and tumor progression in prostate cancer |
| Wurzer, Alexander | Targeted alpha-therapy with 225Ac-labeled PSMA ligands: A preclinical investigation the fate of the decay nuclides |
| Wyatt, Alex | DECIDE Survey (Decision-making, Experience, and Confidence In Determining Genomic Evaluation) – Updated Results by the PRECISION Registry Study Team |
| Xin, Li | Suppressing FZD6 attenuates DNA double-strand break repair and sensitizes advanced prostate cancers to genotoxic agents |
| Xu, Xin | The Transcriptional and Functional Landscape of N6-Methyladenosine in Localized Primary Prostate Cancer |
| Younger, Noah | Identification and characterization of PLUTO-201, a novel IncRNA associated with prostate cancer metastasis |
| Yu, Evan | Phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab plus carboplatin/etoposide or carboplatin/etoposide alone for patients with metastatic neuroendocrine prostate cancer |
| Yu, Evan | Phase 1b/2 KEYNOTE-365 cohort J: Pembrolizumab plus belzutifan or belzutifan monotherapy in patients with docetaxel-treated metastatic castration-resistant prostate cancer |
| Yuan, Wei | Androgen Receptor Blockade in Prostate Cancer Drives Tumour-Fuelling Inflammation Through STING |
| Zhao, Di | CHD1 Loss Hijacks SREBP2-mediated Cholesterol Biosynthesis to Fuel SPOP-deficient Prostate Cancer and Confers Resistance to Castration |
| Zhu, Xiaolin | Investigating SSTR1 as an Actionable Drug Target in Prostate Cancer Resistant to Androgen Receptor Signaling Inhibitors |
| Zorko, Nicholas | Redirecting Natural Killer Cells to Target B7-H3 Using Tri-specific Killer Engagers or Secreted Camelid Nanobody Engagers and Chimeric Antigen Receptors |
